Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Marc A. Pfeffer(Brigham and Women's Hospital), Robert M. Califf(Duke University), John J.V. McMurray(University of Glasgow), Lars Køber(University of Copenhagen), Eric J. Velazquez(Yale University), Steven L. Zelenkofske(Novartis (Switzerland)), Jeffrey D. Leimberger(Duke Medical Center), Marc Henis(Clinical Research Consultants (United States)), Harvey D. White(University of Auckland), Frans Van de Werf(KU Leuven), Karl Swedberg(Brigham and Women's Hospital), Aldo P. Maggioni(Health Care Foundation), Susan Edwards(Janssen (Switzerland)), Jean‐Lucien Rouleau(Montreal Heart Institute), Scott D. Solomon(Brigham and Women's Hospital), Mary Ann Sellers(Duke Medical Center)
Cited by 2,488
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k